In another cohort study [79], the authors assessed how early in the course of Alzheimer’s disease plasma levels of P-tau217 begin to change; these levels were compared with the well-established cerebrospinal fluid and positron emission tomography (PET) tau biomarkers for the early diagnosis of AD. Here, MAPT is linked to Alzheimer disease.